 | | Vol. 8.44 – 25 November, 2020 |
| |
|
|
| Researchers showed that human papillomavirus (HPV)-specific B cell responses were detectable in samples from patients with HPV-positive head and neck cancers, with active production of HPV-specific IgG antibodies in situ.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Scientists analyzed five public scRNA-seq pancreas datasets and performed fluorescence in situ hybridization, Western blotting and immunolocalization for ACE2 with extensive reagent validation on normal human pancreatic tissues across the lifespan, as well as those from COVID-19 cases.
[Cell Metabolism] |
|
|
|
| Investigators assessed antibody and T cell reactivity in convalescent COVID-19 patients and healthy donors sampled both prior to and during the pandemic.
[Immunity] |
|
|
|
| Researchers describe a deep mutational scanning method to map how all amino-acid mutations in the receptor-binding domain affect antibody binding, and applied this method to ten human monoclonal antibodies.
[Cell Host & Microbe] |
|
|
|
| Using organotypic 3D cultures of primary human liver cells, researchers demonstrated that interferon-alpha-2 (IFNα2) significantly increased ACE2 expression and SARS-CoV-2 infectivity in parenchymal cells by >5-fold.
[Science Advances] |
|
|
|
| The authors tested the possibility that the multivalent RNA‐binding nucleocapsid protein from SARS‐CoV‐2 condenses with RNA via liquid‐liquid phase separation, and that N protein could be recruited in phase‐separated forms of human RNA‐binding proteins associated with SG formation.
[EMBO Journal] |
|
|
|
| Scientists investigated additive effect of combination therapy using remdesivir with recombinant soluble ACE2 on Vero E6 and kidney organoids, targeting two different modalities of SARS‐CoV‐2 life cycle: cell entry via its receptor ACE2 and intracellular viral RNA replication.
[EMBO Molecular Medicine] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Using Bacteroides fragilis and its OM-associated polysaccharide A, scientists determined that IFN-β expression was induced via TLR4-TRIF signaling.
[Cell] |
|
|
|
| Using a murine model of malaria and combining single-cell RNA sequencing, mathematical modeling, transplantation assays and intravital microscopy, researchers showed that hematopoiesis was reprogrammed upon infection.
[Nature Cell Biology] |
|
|
|
| The authors generated C. acnes-specific antimicrobial TH17 clones with varying antimicrobial activity against C. acnes, which they correlated by RNA-seq to the expression of transcripts encoding proteins that contribute to antimicrobial activity.
[Journal of Clinical Investigation] |
|
|
|
| Researchers demonstrated that a small accessory protein of contemporary H5N1 and H3N2 influenza A viruses curtailed fulminant cell death of infected human macrophages.
[EMBO Reports] |
|
|
|
| Scientists developed mRNA-based JAK-STAT signaling pathway activity assays to quantitatively measure the cellular immune response on Affymetrix expression microarray data of various types of blood samples from virally infected patients, or vaccinated individuals, and to determine vaccine immunogenicity.
[Frontiers in Immunology] |
|
|
|
|
| The author provides a perspective on the global trends in emerging nanoscale vaccines for infectious diseases and describes the biological, experimental and logistical problems associated with their development, and how immunoengineering can be leveraged to overcome these challenges.
[Nature Nanotechnology] |
|
|
|
| Researchers discuss the timing, nature, and function of the diverse immune responses induced, the onset of immune dysfunction, and the effects of early anti-retroviral therapy administration.
[Immunity] |
|
|
|
| | City of Hope has initiated a Phase I clinical trial that will test one of its investigational SARS-CoV-2 vaccines in healthy volunteers between the ages of 18 and 55 who have not had COVID-19.
[City of Hope] |
|
|
|
|
| Genentech announced that the FDA has approved a supplemental New Drug Application for Xofluza® as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza. Xofluza is the first single-dose influenza medicine approved for post-exposure prophylaxis.
[Genentech (BusinessWire, Inc.)] |
|
|
|
| AbCellera announced that bamlanivimab 700 mg, a human antibody developed through AbCellera’s collaboration with Eli Lilly and Company, was granted authorization by Health Canada under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19.
[AbCellera (BusinessWire, Inc.)] |
|
|
|
|
| May 23 – May 28, 2021
Castelldefels, Spain |
|
|
|
|
|
| | University of Minnesota Medical School – Minneapolis, Minnesota, United States |
|
|
|
| | University of Nantes – Nantes, France |
|
|
|
| | Queen’s University – Kingston, Ontario, Canada |
|
|
|
| | Lerner Research Institute – Cleveland, Ohio, United States |
|
|
|
| | Swiss Federal Institute of Technology in Lausanne – Lausanne, Vaud, Switzerland |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
